Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:3:148.
doi: 10.3332/ecancer.2009.148. Epub 2009 Jun 9.

The evolution of treatment for early breast cancer: what's next?

T Howell  1
Affiliations

The evolution of treatment for early breast cancer: what's next?

T Howell. Ecancermedicalscience. 2009.
No abstract available

PubMed Disclaimer

References

    1. Saphner T, Tormey DC, et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–46. - PubMed
    1. Nolvadex Adjuvant Trial Organisation Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;321(8319):257–61. doi: 10.1016/S0140-6736(83)91683-5. - DOI - PubMed
    1. Schteingart DE, Cash R, et al. Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing’s syndrome. JAMA. 1966;198(9):1007–10. doi: 10.1001/jama.198.9.1007. - DOI - PubMed
    1. Forbes J, on behalf on the ATAC Trialist’s Group ATAC: 100 month median follow-up shows continued superior efficacy and no excess fracture risk for anastrozole compared with tamoxifen after treatment completion. Lancet Oncol. 2008;9(1):45–53. 10.1016/S1470-2045(07)70385-6. - PubMed
    1. Breast International Group (BIG) 1–98 Collaborative Group. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med. 2005;353:2747–57. - PubMed

LinkOut - more resources